Pacific Biosciences of California Inc. Stock
Pacific Biosciences of California Inc. dominated the market today, gaining €0.054 (3.620%).
Currently there is a rather positive sentiment for Pacific Biosciences of California Inc. with 10 Buy predictions and 5 Sell predictions.
With a target price of 10 € there is potential for a 544.99% increase which would mean more than doubling the current price of 1.55 € for Pacific Biosciences of California Inc..
Our community identified positive and negative aspects for Pacific Biosciences of California Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pacific Biosciences of California Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Pacific Biosciences of California Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacific Biosciences of California Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Pacific Biosciences of California Inc. | 3.620% | 13.284% | -55.576% | -83.875% | -83.445% | -93.743% | -76.835% |
MicroVision Inc | -2.870% | 4.570% | -18.865% | -23.793% | -45.642% | -89.161% | 53.557% |
Fonar Corp. New | -0.670% | -0.662% | -24.242% | 7.914% | -15.254% | 5.634% | -15.302% |
Allscripts Healthcare | 5.800% | 0.000% | 6.154% | -37.273% | -25.405% | -45.238% | -20.935% |
Comments
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Sanford C. Bernstein from $9.00 to $2.50. They now have an "outperform" rating on the stock.
Show more
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Show more
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $7.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PACB provided by MarketBeat